Market Overview:
The global wet age-related macular degeneration (AMD) market is expected to register a CAGR of 9.5% during the forecast period, 2018–2030. The market growth can be attributed to factors such as increasing prevalence of AMD, rising geriatric population, and technological advancements in the field of ophthalmology. However, high cost associated with treatment and lack of awareness are some factors that may restrain the growth of this market during the forecast period. Based on type, the wet AMD segment is expected to account for a larger share of the global wet AMD market in 2018. This segment is also projected to register a higher CAGR than other segments during the forecast period. By application, above 75 years age group is estimated to account for majority share in 2018 and it is also projected grow at highest CAGR over next 10 years owing increase life expectancy across globe coupled with growing incidence rate Wet Age Related Macular Degeneration (AMD).
 Industry Outlook.svg)
Product Definition:
Wet age-related macular degeneration (AMD) is a type of AMD that is caused by abnormal blood vessels growing under the retina. These new blood vessels can leak fluid and blood, causing damage to the macula. Wet AMD accounts for about 90% of cases of blindness from AMD.
Wet Age-Related Macular Degeneration (Wet AMD):
Wet AMD is a type of macular degeneration that occurs when the macula, which is located in the center of the retina, deteriorates due to leakage of blood vessels causing bleeding within the eye. The R&D activities in pharmaceutical industry are increasing day by day and many new drugs are developed for various ophthalmic disorders. One such drug named Eylea (aflibercept) was developed for wet age-related macular degeneration (AMD).
Dry Age-Related Macular Degeneration (Dry AMD):
Dry age-related macular degeneration (AMD) is a type of macular degeneration that does not involve any leakage of the choroidal fluid. The disease may progress slowly or may show rapid progression at certain stages. It has been observed that patients diagnosed with dry AMD have a better visual outcome than those diagnosed with wet AMD, which can be attributed to the fact that there is no leakage of choroidal fluid in the former case as compared to the latter.
Application Insights:
The global wet AMD market was dominated by the above 75 years age group in 2016. The application of AMD drugs is highest in this age group as they constitute a higher risk group for developing the disease. Moreover, there is an increase in prevalence of dry AMD among people aged 60 and above as compared to other groups. This trend is expected to continue over the forecast period due to increasing life expectancy and awareness about early detection and treatment ofAMD among individuals especially from developed countries such as U.S., Canada, Germany, France etc.
On basis of application, the global wet AMD market has been segmented into Europe; North America; Asia Pacific; Middle East & Africa; Latin America; and others (Caribbean).
Regional Analysis:
In 2017, North America dominated the global market owing to high prevalence of age-related macular degeneration (AMD) in this region. According to the National Eye Institute (NIH), in U.S., more than 2 million people suffer from AMD every year and it is the leading cause of blindness among older adults.
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to increasing geriatric population base, which increases susceptibility towards various vision disorders including wet age related macular degeneration or dry AMDs.
Growth Factors:
- Increasing elderly population: The global elderly population is expected to grow at a CAGR of 3.8% from 2016 to 2020, and this will drive the demand for Wet AMD treatments.
- Rising awareness about Wet AMD: There is a growing awareness among people about Wet AMD and its treatment options, which is driving the market growth.
- Technological advancements in treatment options: Advancements in technology are helping to improve the diagnosis and treatment of Wet AMD, thereby driving market growth.
- Growing number of clinical studies on new therapies: There has been an increase in the number of clinical studies being conducted on new therapies for Wet AMD, which is aiding market growth.
Scope Of The Report
Report Attributes
Report Details
Report Title
Wet Age Related Macular Degeneration (AMD) Market Research Report
By Type
Wet Age-Related Macular Degeneration (Wet AMD), Dry Age-Related Macular Degeneration (Dry AMD)
By Application
Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027, Above 75 Years, Above 60 Years, Above 40 Years
By Companies
Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), Ophthotech (US), GlaxoSmithKline (US), Alimera Sciences (US), StemCell (Canada), F. Hoffmann-La Roche (Switzerland), Regeneron Pharmaceutical (US), Allergan (Ireland), Adverum Biotechnologies (US), Gilead Sciences (US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Wet Age Related Macular Degeneration (AMD) Market Report Segments:
The global Wet Age Related Macular Degeneration (AMD) market is segmented on the basis of:
Types
Wet Age-Related Macular Degeneration (Wet AMD), Dry Age-Related Macular Degeneration (Dry AMD)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027, Above 75 Years, Above 60 Years, Above 40 Years
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis International (Switzerland)
- Bayer (Germany)
- Acucela (US)
- Neurotech Pharmaceuticals (US)
- Ophthotech (US)
- GlaxoSmithKline (US)
- Alimera Sciences (US)
- StemCell (Canada)
- F. Hoffmann-La Roche (Switzerland)
- Regeneron Pharmaceutical (US)
- Allergan (Ireland)
- Adverum Biotechnologies (US)
- Gilead Sciences (US)
 Market Overview.svg)
Highlights of The Wet Age Related Macular Degeneration (AMD) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Wet Age-Related Macular Degeneration (Wet AMD)
- Dry Age-Related Macular Degeneration (Dry AMD)
- By Application:
- Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
- Above 75 Years
- Above 60 Years
- Above 40 Years
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Wet Age Related Macular Degeneration (AMD) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Wet age related macular degeneration (AMD) is a condition that affects the central vision, usually in people over 50. It causes gradual loss of central vision, which can lead to blindness.
Some of the major players in the wet age related macular degeneration (amd) market are Novartis International (Switzerland), Bayer (Germany), Acucela (US), Neurotech Pharmaceuticals (US), Ophthotech (US), GlaxoSmithKline (US), Alimera Sciences (US), StemCell (Canada), F. Hoffmann-La Roche (Switzerland), Regeneron Pharmaceutical (US), Allergan (Ireland), Adverum Biotechnologies (US), Gilead Sciences (US).
The wet age related macular degeneration (amd) market is expected to register a CAGR of 9.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Wet Age Related Macular Degeneration (AMD) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Wet Age Related Macular Degeneration (AMD) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Wet Age Related Macular Degeneration (AMD) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Wet Age Related Macular Degeneration (AMD) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Wet Age Related Macular Degeneration (AMD) Market Size & Forecast, 2020-2028
4.5.1 Wet Age Related Macular Degeneration (AMD) Market Size and Y-o-Y Growth
4.5.2 Wet Age Related Macular Degeneration (AMD) Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Wet Age-Related Macular Degeneration (Wet AMD)
5.2.2 Dry Age-Related Macular Degeneration (Dry AMD)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
6.2.2 Above 75 Years
6.2.3 Above 60 Years
6.2.4 Above 40 Years
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Wet Age Related Macular Degeneration (AMD) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Wet Age Related Macular Degeneration (AMD) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Wet Age-Related Macular Degeneration (Wet AMD)
9.6.2 Dry Age-Related Macular Degeneration (Dry AMD)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
9.10.2 Above 75 Years
9.10.3 Above 60 Years
9.10.4 Above 40 Years
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Wet Age-Related Macular Degeneration (Wet AMD)
10.6.2 Dry Age-Related Macular Degeneration (Dry AMD)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
10.10.2 Above 75 Years
10.10.3 Above 60 Years
10.10.4 Above 40 Years
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Wet Age-Related Macular Degeneration (Wet AMD)
11.6.2 Dry Age-Related Macular Degeneration (Dry AMD)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
11.10.2 Above 75 Years
11.10.3 Above 60 Years
11.10.4 Above 40 Years
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Wet Age-Related Macular Degeneration (Wet AMD)
12.6.2 Dry Age-Related Macular Degeneration (Dry AMD)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
12.10.2 Above 75 Years
12.10.3 Above 60 Years
12.10.4 Above 40 Years
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Wet Age-Related Macular Degeneration (Wet AMD)
13.6.2 Dry Age-Related Macular Degeneration (Dry AMD)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
13.10.2 Above 75 Years
13.10.3 Above 60 Years
13.10.4 Above 40 Years
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Wet Age Related Macular Degeneration (AMD) Market: Competitive Dashboard
14.2 Global Wet Age Related Macular Degeneration (AMD) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis International (Switzerland)
14.3.2 Bayer (Germany)
14.3.3 Acucela (US)
14.3.4 Neurotech Pharmaceuticals (US)
14.3.5 Ophthotech (US)
14.3.6 GlaxoSmithKline (US)
14.3.7 Alimera Sciences (US)
14.3.8 StemCell (Canada)
14.3.9 F. Hoffmann-La Roche (Switzerland)
14.3.10 Regeneron Pharmaceutical (US)
14.3.11 Allergan (Ireland)
14.3.12 Adverum Biotechnologies (US)
14.3.13 Gilead Sciences (US)
